1. Owens RC, Jr., Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis, 2005;41(Suppl 2):S144-57
2. Van Bambeke F, Michot JM, Van EJ, Tulkens PM. Quinolones in 2005: an update. Clin Microbiol Infect, 2005;11:256-280.
3. Bryskier A. Fluoroquinolones (I) : classification, propriétés physicochimiques, antibactériennes et pharmacocinétiques. In: Anonymous, Encycl Méd Chir. Elsevier, Paris, 1999; p. 8-004.
4. Humbert G, Brumpt I, Montay G, Le Liboux A, Frydman A, Borsa-Lebas F, et al. Influence of rifampin on the pharmacokinetics of pefloxacin. Clin Pharmacol Ther, 1991;50:682-7.
5. Ilo CE, Ilondu NA, Okwoli N, Brown SA, Elo-Ilo JC, Agbasi PU, et al. Effect of chloroquine on the bioavailability of ciprofloxacin in humans. Am J Ther, 2006;13:432-5.